Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech company Nabi Biopharmaceuticals (Nasdaq: NABI) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Nabi's business and see what CAPS investors are saying about the stock right now.

Nabi facts

Headquarters (Founded)

Rockville, Md. (1967)

Market Cap

$216.1 million



Trailing-12-Month Revenue

$30.44 million


CEO Dr. Raafat Fahim (since 2008)

Chief Medical Officer Dr. Paul Kessler (since 2007)

Return on Equity (Average, Past 3 Years)



$100.5 million / $0


Novartis (NYSE: NVS)

Pfizer (NYSE: PFE)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95% of the 190 members who have rated Nabi believe the stock will outperform the S&P 500 going forward. These bulls include StockDonStan and All-Star zzlangerhans, who is ranked in the top 1% of our community.

Earlier this year, StockDonStan touched on the potential of Nabi's nicotine addiction treatment: "When NicVax hits the market by the end of 2012, this company is going to be widely known, and widely owned. The product is a game changer and NABI will save your portfolio while saving your life (from the bad habit that is so enjoyable)."

Over the next five years, in fact, Nabi is expected to grow its bottom line at a solid rate of 15% annually. That's faster than much larger competitors like Novartis (5%) and Pfizer (3%).

CAPS All-Star and biotech expert zzlangerhans elaborates on the bull case:

Nabi is a new guilty pleasure. A vaccine to treat nicotine addiction? It's just crazy enough to work. Results of two phase III trials of NicVAX are expected in H2 2011 and H1 2012 respectively, and [GlaxoSmithKline (NYSE: GSK)] bought into the story enough to throw in 40M up front. With the big catalyst approaching, the stock finally staggered under the 5-6 range of the last one and a half years.

What do you think about Nabi, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Novartis, Pfizer, and GlaxoSmithKline. The Motley Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.